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Aptamers represent an emerging strategy to deliver cargo molecules, including dyes, drugs, proteins or even genes, into
specific target cells. Upon binding to specific cell surface receptors aptamers can be internalized, for example by
macropinocytosis or receptor mediated endocytosis. Here we report the in vitro selection and characterization of RNA
aptamers with high affinity (Kd = 20 nM) and specificity for the human IL-6 receptor (IL-6R). Importantly, these aptamers
trigger uptake without compromising the interaction of IL-6R with its natural ligands the cytokine IL-6 and glycoprotein
130 (gp130). We further optimized the aptamers to obtain a shortened, only 19-nt RNA oligonucleotide retaining all
necessary characteristics for high affinity and selective recognition of IL-6R on cell surfaces. Upon incubation with IL-6R
presenting cells this aptamer was rapidly internalized. Importantly, we could use our aptamer, to deliver bulky cargos,
exemplified by fluorescently labeled streptavidin, into IL-6R presenting cells, thereby setting the stage for an aptamer-
mediated escort of drug molecules to diseased cell populations or tissues.
Introduction
Interleukin-6 (IL-6) is a multifunctional cytokine that is involved
in many immune and inflammatory responses. It belongs to the
family of the four-helix bundle cytokines.
1 IL-6 interacts with its
natural receptor, namely IL-6R, and two molecules of the
glycoprotein 130 (gp130), the transducer of the IL-6 signal.
2
IL-6R appearance is restricted to a few cell types, including
hepatocytes, monocytes, macrophages and some lymphocytes.
2 In
contrast, gp130 can be found on nearly all cell types. Cells that do
not produce the membrane bound IL-6R (mIL-6R) can be
stimulated by IL-6 via a soluble form of the IL-6R (sIL-6R). The
sIL-6R is produced by cells positive for mIL-6R via alternative
splicing or proteolytic cleavage of the membrane bound form.
3,4
The sIL-6R in complex with IL-6 enables IL-6R lacking cells to
respond to IL-6 mediated signaling.
2
IL-6 and its receptor are involved in the progression of various
inflammatory diseases, such as Crohn’s disease and rheumatoid
arthritis (RA), and certain cancers, for example multiple myeloma
or hepatocellular carcinoma.
5 One promising therapeutic strategy
to tackle the mentioned diseases could be the specific delivery of
drugs into cells by targeting IL-6R.
Aptamers are nucleic acids (DNA or RNA) consisting of about
15–100nt, which are able to bind target molecules with high
affinity and specificity, exhibiting Kd values in the picomolar
range. Aptamers can be obtained by an in vitro selection process,
termed SELEX (systematic evolution of ligands by exponential
enrichment).
6,7 Starting with a combinatorial oligonucleotide
library containing up to 10
15 different nucleic acid species, the
SELEX process leads to the enrichment of an oligonucleotide
population (polyclonal aptamers) that interacts with the target
molecule due to defined three-dimensional structures. In respect
of recognition properties aptamers are comparable to antibodies
even though they reveal remarkable advantages, such as low
immunogenicity and toxicity, longer shelf-life, and lower produc-
tion costs. Up to now, aptamers were evolved for a wide variety of
target molecules, including ions,
8 fluorescent dyes,
9 antibiotics,
10
peptides,
11 and proteins.
12 Furthermore aptamers targeting
viruses
13 as well as whole cells
14 have previously been selected
and characterized for potential therapeutic applications. Next to
their appliance in diagnostics, aptamers can serve as stimulating
15
or inhibiting
16 ligands, respectively. One very promising approach
is the application of cell-specific aptamers as delivery vehicles for
drug molecules into target cells or tissues. One auspicious example
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is the successful selection of an RNA aptamer binding to PSMA
(prostate-specific membrane antigen) presented on the surface
of prostate cancer cells.
17 Upon binding, anti-PSMA aptamers
undergo receptor-mediated internalization. Coupling those nuc-
leic acids to cargo molecules, such as toxins,
18 siRNAs,
19 chemo-
therapeutics, and nanoparticles
20 improves delivery to the cells of
interest. This can allow to lower the dose required for effective
treatment and is therefore considered a promising therapeutic
approach which had been validated in animal studies.
21
Thus, aptamers are very promising tools for cell-specific
targeting. However, there is only a limited number of appropriate
representatives to date. Therefore, new aptamers specific for cell
surface proteins or whole cells are urgently needed.
We set out to enhance the toolbox of cell-targeting and drug
delivering molecules. Thus, we decided to select aptamers specific
for the human IL-6R, a cell surface receptor presented on a variety
of cells often connected to numerous diseases, like the already
mentioned multiple myeloma. Our studies yielded a 19-nt RNA
aptamer, namely AIR-3A, which specifically recognizes cells that
present IL-6R. This aptamer is able to transport cargo molecules
of different sizes, exemplified by fluorescent dyes and streptavidin,
into living IL-6R presenting cells. In view that IL-6 actively
participates in inflammation associated cancer,
22,23 selective
targeting of IL-6R presenting tumor cells with toxic substances
coupled to aptamers might be a valuable strategy to broaden
established IL-6 or IL-6R directed treatment regimens.
Results
In vitro selection of sIL-6R-specific RNA aptamers. Aiming for
RNA aptamers binding to cells that present IL-6R on their sur-
face, we used the extracellular soluble part of the receptor (sIL-6R)
as target molecule during the in vitro selection experiment. In the
first selection cycle the RNA library R1 containing 10
13 individual
RNA molecules was incubated with sIL-6R, immobilized on
magnetic beads. RNA molecules binding to sIL-6R were captured
by magnetic separation and amplified by RT-PCR. After in vitro
transcription the enriched RNA library was used as starting
material for the subsequent selection cycle. The stringency of
the selection process was enhanced gradually by increasing the
number of washing steps with each additional selection cycle.
After 16 selection rounds the enriched RNA library was analyzed
for sIL-6R binding by filter retention analysis (FRA), which
revealed a significantly increased affinity of the cycle 16 RNA for
sIL-6R in comparison to the initial RNA library R1 (Fig. S1).
Subsequently, the corresponding cycle 16 dsDNA library was
cloned and the sequences of 20 clones were determined (Fig.1).
We identified six individual sIL-6R-binding RNA aptamers all
sharing a G-rich consensus motif.
Affinity and specificity of the RNA aptamer AIR-3 for sIL-6R.
Initial FRAs revealed that among other tested aptamers the
RNA aptamer AIR-3 exhibited the highest affinity for sIL-6R
(Table S1 and Fig. S2). We further determined the dissociation
constant (Kd) for AIR-3 binding to sIL-6R more precisely by
repeating the FRA for ten times. Thereby, the initial RNA library
R1 served as a control. After quantification resulting curves
were fitted assuming a 1:1 binding stoichiometry between both
interacting partners. AIR-3 revealed a high affinity for sIL-6R
with a calculated Kd-value of 19.7 ± 4.2 nM (Table 1 and Fig.2).
No binding of the RNA library R1 was detectable. Further FRAs
revealed that AIR-3 did not bind to the control proteins IL-6 and
lysozyme (data not shown).
Influence of AIR-3 on the interactions between sIL-6R and its
ligands IL-6 and gp130. To determine whether aptamer AIR-3
competed with the cytokine IL-6 for binding to sIL-6R, filter
Figure1. Sequences of RNA aptamers binding the soluble part of the IL-6 receptor (sIL-6R). Sequences are printed in 5’–3’ direction omitting flanking
primer-binding sites. Bold letters indicate conserved positions. F, frequency; consensus sequence is underlined and additionally given below. H: A, C or U;
W: A or U.
Table1. Aptamer—target interactions
Aptamer Target Method
1 Kd (nM)
AIR-3 sIL-6R FRA 19.7 ± 4.2
AIR-3A Hyper-IL-6 FRA 60.4 ± 16.0
AIR-3A Cells FCM 8.5 ± 1.0
1FRA, filter retention assay; FCM, flow cytometry
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retention assays were employed. Increasing amounts of sIL-6R
were pre-incubated with or without its ligand IL-6. Constant
amounts of radioactively labeled aptamer AIR-3 were added.
Figure3A displays the results of the FRAs revealing no
competition between IL-6 and the RNA aptamer AIR-3 for
binding to sIL-6R.
Knowing that the aptamer AIR-3 specifically interacts with
sIL-6R even in the presence of its natural ligand IL-6, we inves-
tigated the interaction of aptamer AIR-3 with the designer
cytokine Hyper-IL-6, a fusion protein consisting of human IL-6
and the human sIL-6R connected by a flexible polypeptide
chain.
24 First, we performed FRAs to proof the ability of AIR-3 to
interact with Hyper-IL-6 (Fig. S3).
The ability of aptamer AIR-3 to disrupt the interaction
between Hyper-IL-6 and the second receptor subunit gp130 was
examined by electrophoretic mobility shift assay (EMSA). This
EMSA confirmed that AIR-3 did bind to Hyper-IL-6 as
illustrated by a retarded migration rate in the native PAGE if
compared with sole RNA (Fig.3B, lanes 1 and 2). Additionally, a
supershift confirmed the interaction between AIR-3 and Hyper-
IL-6 complexed with gp130 (Fig.3B, lane 4). The complex
formation between Hyper-IL-6 and gp130 was not disrupted by
AIR-3. No unspecific binding of AIR-3 to gp130 could be
observed (Fig.3B, lane3).
Minimization of the RNA aptamer AIR-3. All identified sIL-
6R specific aptamers contained a conserved G-rich motif (Fig.1).
According to this observation the aptamer AIR-3 was truncated
finally yielding a 19 nucleotides short aptamer, termed AIR-3A
(5'-GGGGAGGCUGUGGUGAG17G18G-3'). Three variants of
AIR-3A namely G17U, G18U and G17U/G18U were generated
to serve as controls. These variants bear G to U nucleotide
exchanges at position 17, position 18 or at both positions,
respectively. The abilities of these four truncated RNA molecules
to bind Hyper-IL-6 were subsequently determined by FRA
(Fig. S4, Table 1). The truncated aptamer AIR-3A exhibited a
high affinity for Hyper-IL-6, whereas the variants G17U, G18U
and G17U/G18U did not show any significant binding.
Structural analyses of AIR-3A and its derived variants. In a
first CD spectroscopic experiment the spectrum of the RNA
aptamer AIR-3A, solved in 1  PBS (containing Na
+ or K
+ ions),
revealed two main peaks, a maximum at 265 nm and a minimum
at 240 nm (Fig.4A), suggesting the formation of G-quadruplexes
with parallel strand orientation.
25,26 The variants G17U, G18U,
and G17U/G18U, each solved in PBS as well, did clearly show a
Figure2. Aptamer AIR-3 binds the soluble IL-6 receptor (sIL-6R) with
high affinity. Filter retention assays. Constant amounts (,1 nM) of
32P-radioactively labeled aptamer AIR-3 (red diamonds) and RNA starting
library R1 (black circles) were incubated with increasing amounts of
sIL-6R (0–300 nM). Protein-bound RNA was visualized by autoradio-
graphy. Fractions of bound RNA molecules were plotted against the
concentration of sIL-6R (logarithmic scale). Data points represent mean
values of 10 independent measurements.
Figure3. Aptamer AIR-3 does not compete with IL-6 or gp130 for binding
to IL-6R. (A) Filter retention assays. Constant amounts of IL-6 (1 mM) were
pre-incubated with increasing amounts of sIL-6R (0–300 nM) before
radiolabeled aptamer AIR-3 (,1 nM) was added to the complex. For
data evaluation see legend to Figure2. (B) Interaction of aptamer AIR-3
(,1 nM) with Hyper-IL-6 (500 nM) or with Hyper-IL-6/gp130 complex
(1:2 stoichiometry) analyzed by gel-electrophoretic mobility shift assay.
Lanes 1 and 5, free aptamer; remaining lanes contained aptamer + 500 nM
Hyper-IL-6 (2), + 1 mM gp130 (3) or both proteins (4).
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decrease in signal intensity at the characteristic wavelength. The G
to U nucleotide exchanges seemed to destabilize or destruct the
G-quadruplexes in all variants.
The formation of stable G-quadruplexes requires the presence
of special metal ions like K
+ or Na
+.
27 Therefore we measured the
CD spectra of AIR-3A in T-HCl buffer omitting monovalent
sodium and potassium cations, respectively (Fig.4B). The
quadruplex formation was obviously reduced as the resulting
peak amplitudes of the spectra decreased. After addition of potas-
sium or sodium chloride both peaks increased again indicating
that these ions are prerequisites for structural stability.
To confirm the potential G-quadruplex folding of AIR-3A we
performed UV melting transitions at 295 nm.
28 First, we solved
AIR-3A in 10 mM Tris buffer (pH 7.5) including 5 mM KCl.
We could show that the UV melting profile (Tm value 48.4°C)
was characterized by a hypochromic shift as typically observed
for nucleic acids containing G-quadruplex structures (Fig.4C and
Table S2). We evaluated the stability of the AIR-3A G-quadruplex
by determining its melting temperatures at different potassium
concentrations (0 mM, 1 mM, and 10 mM, respectively). The
melting temperature decreased as a result of the reduction of the
KCl concentration (Fig.4C and Table S2). In absence of K
+
cations melting curves did not show any hypochromic shift.
Therefore it was not possible to determine the corresponding Tm
value. Thus folding was significantly dependent on K
+ cations.
The melting temperature of AIR-3A did not dependent on
RNA concentration over a range from 1 to 10 mM since the Tm
corresponding values did not change significantly (Fig.S5A and
Table S2).
All three variants G17U, G18U, and G17U/G18U did not
exhibit a hypochromic shift within the corresponding UV melting
profiles neither in absence nor in presence of 5 mM KCl
(Fig. S5B, Table S2). Therefore we could not calculate any Tm
values.
Taken together, these results indicated that only AIR-3A
exhibited a stable intramolecular G-quadruplex under physio-
logical conditions.
Interaction of AIR-3A with IL-6R presenting cells. Binding of
AIR-3A to BAF/gp130/IL6R/TNF cells. We subsequently deter-
mined whether AIR-3A was able to bind IL-6R presenting cells.
Therefore, we used two murine cell lines, BAF/gp130/IL6R/
TNF-cells, a parental pro-B cell line transfected with the cDNA of
human gp130, human IL-6R, and TNF, as well as BAF/gp130
cells, that were transfected solely with the cDNA of human
gp130, the latter serving as control.
Atto647N-labeled aptamer AIR-3A and the control variant
G17U were assayed for their binding capacities on IL-6R
presenting BAF/gp130/IL6R/TNF cells by flow cytometry.
AIR-3A but not G17U did bind to those cells (Fig.5A). Both
RNAs failed to bind to cells lacking IL-6R (Fig.5B). IL-6R
expression on BAF/gp130/IL6R/TNF cells but not on BAF/
gp130 cells was confirmed using a monoclonal human IL-6R
specific antibody. This antibody did bind to BAF/gp130/IL6R/
TNF cells but not to IL-6R-negative BAF/gp130 cells (Fig.5C
and D, respectively).
To analyze whether the binding capacity of the RNA aptamer
in serum containing medium might be disturbed by contaminat-
ing RNases we performed binding assays in selection buffer, cell
culture medium and serum containing medium at 4°C or 37°C,
Figure4. Structural analyses of AIR-3A and its variants. (A) CD
spectroscopic analyses of AIR-3A, G17U, G18U and G17U/G18U (5 mMi n
PBS). (B) CD spectrum of AIR-3A (5 mM) in PBS or Tris buffer (50 mM)
without or in the presence of potassium or sodium ions (100 mM each),
respectively. (C) Melting profile of AIR-3A (2.5 mM; taken at 295 nm) in
10 mM Tris buffer containing 1 mM, 5 mM or 10 mM KCl, respectively.
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Figure5. Aptamer AIR-3A specifically binds to BAF/gp130/IL6R/TNF cells presenting the human IL-6 receptor. (A)/(B) Interactions of the IL-6R specific RNA
aptamer AIR-3A (Atto647N-labeled, red) or the variant G17U (Atto647N-labeled, black) with BAF/gp130/IL6R/TNF cells (A) and BAF/gp130 cells (B) were
analyzed by flow cytometry. Binding of AIR-3A was restricted to BAF/gp130/IL6R/TNF cells. BAF/gp130 cells do neither interact with RNA aptamer AIR-3A
nor with the variant G17U, respectively (grey, unstained cells). (C)/(D) Cell surface expression of human IL-6R on BAF/gp130/IL6R/TNF cells (C) and
BAF/gp130 cells (D) was confirmed by flow cytometry analyses using an antibody specific for human IL-6R. For detection a FITC-labeled goat anti-mouse
antibody was used. IL-6R detection was restricted to BAF/gp130/IL6R/TNF cells. For BAF/gp130 cells no IL-6R expression was detectable (grey, unstained
cells; orange, mouse anti-hIL6R antibody; black, isotype control). (E) AIR-3A binds to BAF/gp130/IL6R/TNF cells in a concentration dependent manner.
Increasing amounts (0–150 nM) of AIR-3A (Atto647N-labeled, red) and variant G17U (Atto647N-labeled, black) were incubated with BAF/gp130/IL6R/TNF
cells. Binding was monitored by flow cytometry. Mean fluorescence intensities were plotted against corresponding RNA concentrations. The apparent
Kd-value of AIR-3A binding to IL-6R presenting cells was calculated to be 8.5 ± 1 nM.
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respectively (Fig. S6). In all cases no interference with aptamer
binding could be detected within one hour of incubation.
We next determined the apparent Kd-value for the interaction
of AIR-3A with IL-6R on corresponding cells. Therefore we
incubated 500,000 BAF/gp130/IL6R/TNF cells with increasing
amounts of fluorescently labeled aptamer AIR-3A or the non-
binding control G17U. Flow cytometry analysis revealed an
apparent affinity (Kapp) of 8.5 ± 1.0 nM for AIR-3A (Fig.5E and
Table 1).
Influence of PMA-stimulated IL-6R-shedding on AIR-3A binding.
To further analyze if the human IL-6R is indeed the target mole-
cule of AIR-3A on BAF/gp130/IL6R/TNF cells we pretreated
the cells with PMA (phorbol-12-myristate-13-acetate). PMA is
known to stimulate the shedding of the IL-6R ectodomain from
cells expressing the membrane bound IL-6R by activating the
protease ADAM17. Subsequently, this leads to the release of
sIL-6R from the cell surface.
29
In accordance with our interaction data, PMA treatment, led to
a significantly reduced binding of aptamer AIR-3A to target cells
(Fig.6A). To confirm the shedding of the IL-6R on BAF/gp130/
IL6R/TNF cells treated with PMA we performed flow cytometry
analyses using antibodies against human IL-6R and gp130, as a
control, respectively. Thus we could show that PMA stimulation
did only influence the expression pattern of IL-6R on the cell
surface and not of gp130 (Fig.6B and C).
Binding of AIR-3A to further cell lines. We broadened the
analysis of AIR-3A binding to further cell lines presenting or
lacking IL-6R (Fig. S7). Flow cytometric profiles indicated that
AIR-3A as well as the IL-6R-binding mAb recognized their target
on IL-6R-presenting U937 cells. In contrast the same probes
failed to bind HeLa and HEK293 cells, respectively.
IL-6 receptor mediated internalization of derivatized aptamer
AIR-3A. Internalization of fluorescently labeled AIR-3A. In order to
test the applicability of aptamer AIR-3A to serve as delivery
vehicle, we analyzed whether the AIR-3A is being taken up
through an active process by BAF/gp130/IL6R/TNF cells.
To achieve this we first incubated fluorescently labeled AIR-3A
with target cells. Potential internalization was visualized by con-
focal fluorescence microscopy (Fig.7). Intracellular fluorescence
Figure6. AIR-3A specifically binds to IL-6R on BAF/gp130/IL6R/TNF cells.
(A) BAF/gp130/IL6R/TNF cells treated without (red) or with PMA (black)
were analyzed for binding of AIR-3A (Atto647N-labeled). Untreated
BAF/gp130/IL6R/TNF cells revealed a higher binding of IL-6R specific
aptamer AIR-3A in comparison to PMA-treated cells (grey, unstained
cells). (B) BAF/gp130/IL6R/TNF cells without (orange) or with (black) PMA
(phorbol-12-myristate-13-acetate) treatment were analyzed for IL-6R
presentation using a mouse antibody specific for human IL-6R. For
untreated BAF/gp130/IL6R/TNF cells a higher IL-6R presentation on the
cell surface was detectable in comparison to PMA-stimulated cells.
(C) PMA-treated (black) or untreated (green) BAF/gp130/IL6R/TNF cells
were analyzed for gp130 presentation using a mouse antibody specific
for human gp130. Flow cytometry analyses revealed the same
presentation pattern of gp130 on both cell types. Consequently, the
production of gp130 was not influenced by PMA. For detection a
FITC-labeled goat anti-mouse antibody was used.
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signals were detected only when incubated with cells presenting
IL-6R. Binding of fluorescently labeled G17U to BAF/gp130/
IL6R/TNF cells was not detectable (data not shown).
To reveal time depending binding of AIR-3A to IL-6R pre-
senting cells fluorescently labeled RNAs were incubated with
BAF/gp130/IL6R/TNF or BAF/gp130 cells for up to 8 h in
serum containing medium. If incubated at 37°C AIR-3A binding
to receptor presenting cells was detectable within less than 2 min
reaching the maximal signal intensity after around 4 h (Fig.8A).
The interaction of G17U with these cells as well as the interaction
of both RNAs with BAF/gp130 cells were much lower and
showed different kinetics. At 4°C, however, only AIR-3A was able
to bind to IL-6R presenting cells (Fig.8B). The maximal signal
intensity peaked earlier (30 min) but remained significantly lower
if compared with 37°C.
IL-6R-mediated internalization of aptamer-streptavidin complexes.
After having shown that the aptamer is able to mediate membrane
translocalization of a fluorescence dye, we next investigated whether
larger cargos, such as streptavidin, could also be translocated by
AIR-3A. We therefore built-up a ternary complex of AIR-3A, a
fluorescence dye (Atto635), and streptavidin (Fig.9A). The former
two components, both biotinylated, were mixed in a 3:1 ratio and
subsequently combined with one part of streptavidin. This mixture
was then incubated with IL-6R presenting cells. Complex formation
was monitored by native PAGE (Fig. S8). The corresponding
ternary complex in which AIR-3A was replaced by the inactive
variant G17U was used as negative control. As expected the G17U-
streptavidin-Atto635 control did not interact with the cells whereas
the AIR-3A-streptavidin-Atto635 complex bound to BAF/gp130/
IL6R/TNF cells (Fig.9B).
Figure7. Internalization of AIR-3A bound to BAF/gp130/IL6R/TNF cells. Cells were incubated with Atto645N-labeled AIR-3A for 30 min at 37°C and
visualized via confocal laser scanning microscopy. All panels show fluorescence micrographs at various depths within the cells (z-stack starting from
upper left to lower right; stack size: 15.6 mm; scanning step depths: 1.3 mm; scale bars: 20 mm).
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Furthermore, confocal microscopy revealed that even the large
complex was internalized upon target cell recognition (Fig.10).
However, internalization was found to be less pronounced com-
pared with the dye-construct and the residual portion still bound
to the cell surface could be removed by trypsin treatment
(Fig.10A and B). Incubation on ice did not result in inter-
nalization clearly indicating that the process is receptor-mediated
rather than related to simple passive diffusion (Fig.10C and D).
Discussion
In vitro selections of aptamers have been performed for more than
two decades. During this period a large variety of aptamers has
been successfully selected and applied for numerous purposes
both in vitro and in vivo. Aptamers have been used in vitro for
protein purification
30 and quantification
31 or for enzyme-linked
oligonucleotide assays.
32 The in vivo usage included inhibition of
enzymes,
33 interference with ligand-receptor interactions
16 or
imaging purposes.
34 More recently, aptamers, that bind to cell
surface proteins, became attractive tools to regulate the function of
their protein targets in an agonistic
15 or antagonistic manner.
16,35
Since most cell-surface proteins undergo recycling processes,
such as ligand-induced internalization, aptamers that recognize
and bind to those cell-surface proteins might be infiltrated into
corresponding cells and thus be used for a cell specific delivery of
cargo molecules. This would open new strategies for aptamer-
based drugs.
Currently, delivery approaches of cargo molecules into target
cells comprise both covalently and non-covalently connected
constructs. Non-covalent assemblies include the encapsulation of
siRNAs into lipid particles.
36 Covalent conjugation was also
successfully performed for siRNAs and lipids, like cholesterol.
37
One major drawback in most cases, however, is the non-specific
cellular uptake of these conjugates. To gain cell-specific uptake
and to reduce off-target effects, strategies for selective drug
deliveries are desirable.
So far, only few aptamers have been used to specifically escort
cargo molecules, like siRNAs,
19 protein toxins,
18 chemotherapeu-
tics,
38 nanoparticles,
39 and enzymes,
40 to or into specific cells or
tissues of interest.
As already mentioned in the introduction, one of the best-
studied aptamers for cell-specific delivery is the aptamer for
prostate specific membrane antigen (PSMA), a well-known tumor
marker of prostate cancer.
17 Another promising delivery approach
deals with the gp120 aptamer that was coupled to siRNAs specific
for HIV-mRNAs and subsequently used to interfere with virus
infectivity and reproduction
12 (for review see ref. 41).
Thus, aptamers that target cell surface proteins comprise a
promising and emerging class of molecules that might be used for
the targeted delivery of drug-like agents to special cells or tissues,
going along with a high therapeutic potential and a relatively low
cytotoxicity. The development of further aptamers to specifically
be internalized by cells would be a very attractive strategy for cell-
specific escort purposes and therapies.
In this study, we describe the selection and characterization of
RNA aptamers targeting the human Interleukin-6 receptor
(IL-6R). This receptor is primarily produced by hepatocytes,
monocytes, macrophages and some lymphocytes.
2 Its native
ligand is the cytokine IL-6. This cytokine plays a pivotal role in a
variety of medical conditions, for example in multiple myeloma
IL-6 was shown to be responsible for the progression of this type
of cancer.
42 Additionally, in the case of IL-6 it was recently shown
that F4/80 tumor infiltrating macrophages secreted high amounts
of IL-6, which increased STAT3 phosphorylation and cellular
growth in the tumor cells.
22,23 Therefore, targeting IL-6R
expressing tumor cells with an IL-6R specific aptamer carrying a
cellular toxin or other interfering molecules seems to be a novel
and promising strategy.
To facilitate in vitro selection of IL-6R-specific aptamers we
used the recombinantly produced soluble extracellular portion of
the receptor, sIL-6R. Sixteen rounds of in vitro selection yielded
Figure8. Time course of AIR-3A binding to IL-6R presenting cells. Cells
were incubated with Atto647N-labeled oligonucleotides (25 nM) at
37°C (A) or 4°C (B) for up to 8 h in serum containing medium and
subsequently analyzed by flow cytometry. Median fluorescence
intensities (MFI) resulting from two independent measurements were
plotted against the incubation time.
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six sIL-6R-binding RNA aptamers (Fig.1). Aptamer AIR-3
revealed best binding properties with high affinity and selectivity.
Competition experiments (Fig.3) revealed that AIR-3 did neither
interfere with cytokine IL-6 nor with gp130 recognition of IL-6R.
Thus, the aptamer AIR-3 seemed not to interfere with the IL-6
mediated formation of the active signaling IL-6R complex.
For minimization of the IL-6R aptamers we took into account
that the initially obtained six individual aptamers shared one
common G-rich consensus motif of 19 nucleotides (Fig.1).
Consequently, aptamer AIR-3 was truncated from 106 to 19 nt,
the latter corresponding to a molecular weight of only 6 kDa. This
shortened version, named AIR-3A, still bound IL-6R with high
affinity (Table 1). The variants G17U, G18U and G17U/G18U
derived from AIR-3A by replacing a G to U in position 17, 18 or
in both positions, lacked any binding activities.
As it is known that G-rich regions in nucleic acids can adopt
G-quadruplex conformations we wanted to inquire if structural
changes in G17U, G18U and G17U/G18U might have caused
the loss of their ability to bind IL-6R and therefore performed CD
spectroscopic and UV-melting analyses. AIR-3A as well as G17U
in turn fulfilled the criteria for the formation of G-quadruplexes as
both possessed a minimum of four interspersed GG dinucleotides.
CD analyses and UV-melting studies showed that AIR-3A but
not G17U adopted a parallel G-quadruplex structure (Fig.4,
Table S2). Thus a structural distortion of the G-quadruplex was
probably the reason why G17U lost its affinity for IL-6R. The
variants G18U and G17U/G18U did not fulfill the criteria for
G-quadruplex formation. Indeed they did not adopt G-quadruplex
structures as revealed by biophysical structural analyses.
Next to these structural investigations we wanted to deepen our
knowledge about the functional properties of AIR-3A. Using flow
cytometry we revealed that AIR-3A, but not the control G17U,
did bind to Baf/gp130/IL-6R/TNF cells that were stably trans-
fected with the cDNA encoding human IL-6R (Fig.5). AIR-3A
as well as G17U did not bind to Baf/gp130 cells lacking IL-6R.
However, in case of U937 cells that endogenously present about
2.800 IL-6R molecules on their surface,
43 AIR-3A did bind
(Fig. S7). Contrarily, cells that do not present IL-6R endo-
genously, like HEK293 cells, or only a few IL-6R molecules, like
HeLa cells,
44 were neither bound by AIR-3A nor by an IL-6R-
specific monoclonal antibody.
We further analyzed whether the medium components,
especially serum, could interfere with the interaction between
IL-6R-presenting cells and AIR-3A. We could not detect any
difference between selection buffer, medium and serum contain-
ing medium (Fig. S6). Advantageously, G-quadruplex structures
can reveal enhanced stabilities to serum and cellular nucleases
compared with differently structured nucleic acid molecules.
45
However, for future in vivo applications, additional modification
of the aptamer might be a prerequisite to further improve stability
and shelf-life of AIR-3A.
Next to cell-specific binding we could show that fluorescently
labeled AIR-3A was additionally internalized by IL-6R-presenting
cells at 37°C and not at 4°C (Figs.7 and 8). Due to the fact that
IL-6R endocytosis also only occurs at 37°C,
46,47 we conclude a
temperature- and receptor dependent endocytotic process for
AIR-3A uptake. Alternative forms of endocytosis like macro-
pinocytosis
48 presumably can by excluded in case of AIR-3A, at
least within the first minutes. However, the exact mechanism of
the AIR-3A uptake remains to be verified. There are only few
studies that propose a model for aptamer uptake. In cancer cells,
Reyes-Reyes et al. for example proved macropinocytosis as basic
Figure9. Binding of AIR-3A-streptavidin complexes to BAF/gp130/IL6R/TNF cells. (A) Schematic illustration of aptamer-streptavidin-Atto635 conjugates.
Aptamers and Atto635 were covalently modified with a biotin group and non-covalently assembled with streptavidin in a 3:1:1 ratio to gain ternary
complexes. (B) Ternary complexes consisting of streptavidin, Atto635 and AIR-3A or G17U, respectively, were analyzed for binding to BAF/gp130/IL6R/
TNF cells. Flow cytometric analyses revealed clearly binding of AIR-3A-streptavidin-Atto635 complexes (blue), but not any binding of the G17U-
streptavidin-Atto635 complexes (black). Interaction of the IL-6R specific RNA aptamer AIR-3A (Atto647N-labeled, red) with BAF/gp130/IL6R/TNF cells
served as positive control (grey, unstained cells).
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process for the uptake of AS1411, a nucleolin binding G-rich
DNA aptamer serving as anticancer agent.
45 For successful cargo
delivery by aptamers into target cells sole uptake is not the only
hurdle to overcome. Furthermore the endosomal escape—the
transfer of cargo molecules via the endosomal membrane into
the cytoplasm—is an additional prerequisite. Currently, all
conceivable steps involved are poorly understood.
49
In the study described here the IL-6R specific RNA aptamer
AIR-3A was proven to serve as specific carrier for the inter-
nalization of larger cargos, exemplified by the protein streptavidin
Figure10. IL-6R-mediated internalization of AIR-3A-streptavidin complexes by BAF/gp130/IL6R/TNF cells. (A) and (B) BAF/gp130/IL6R/TNF cells were
incubated with Atto645N-labeled AIR-3A-streptavidin complexes for 30 min at 37°C without (A) or (B) with subsequent trypsin digestion. After incubation
at 37°C internalized complexes could be detected. (C) and (D) BAF/gp130/IL6R/TNF cells were incubated with Atto645N-labeled AIR-3A-streptavidin
complexes for 30 min at 4°C without (C) and with (D) subsequent trypsin treatment (degradation of surface proteins) before microscopy. After incubation
at 4°C no internalized complexes could be detected. For each experiment panels of fluorescence micrographs, transmitted light micrographs and
overlays of both (from left to right) are shown. (scale bars: 20 mm)
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(MW about 67,2 kDa). In other words AIR-3A—only 19 nt
short—was capable of specifically carrying a cargo protein with a
molecular weight 10 times higher than its own into cells. Due to
the high potential of AIR-3A to additionally serve as delivery
vehicle for siRNAs, toxins, or nanoparticles, this aptamer might
become interesting for the treatment of various diseases connected
to IL-6R presenting cells. AIR-3A may also serve as a tool to study
cellular uptake of nucleic acids in greater detail on its own.
Further structural investigations of AIR-3A and its derivatives,
including crystallization of free aptamer or in complex with
sIL-6R as well as the selection of aptamers capable of blocking the
active receptor are under way.
Materials and Methods
Chemicals. Unless otherwise noted, all chemicals were purchased
from Sigma-Aldrich. Buffers were prepared using de-ionized water
obtained from a water purification system (Millipore). Selection
buffer for SELEX consisted of 137 mM NaCl; 2.7 mM KCl;
6.5 mM Na2HPO4; 1.5 mM KH2PO4 and 3 mM MgCl2 at
pH 7.5.
Oligonucleotides. See Table 2. (1) All RNAs were synthesized,
optionally modified (5'-Biotin, 5'-Atto647N, or 5'-Cy5), and
purified by IBA. (2) DNA library R1, containing 60 randomized
nucleotides (N60), and corresponding primers were purchased
from Metabion. The T7 promoter region is underlined.
Cell lines. BAF/gp130 cells and BAF/gp130/IL6R/TNF cells
were kindly provided by Dr. Athena Chalaris (University Kiel,
Germany). Those and all other cell lines used were cultured at
37°C and 5% CO2 in Dulbecco’s Modified Eagle’s Medium
(DMEM, PAA, E15–810) supplemented with 10% fetal bovine
serum (FBS, PAA, K41–001), penicillin (60 mg/L, PAA, P11–
010) and streptomycin (100 mg/L, PAA, P11–010). Culture
medium for BAF/gp130 cells was further supplemented with
Hyper-IL-6 (10 ng/mL).
24 Culture medium for BAF/gp130/IL-
6R/TNF cells was further supplemented with Interleukin-6
(10 ng/mL). For stimulation of BAF/gp130/IL6R/TNF cells with
phorbol-12-myristate-13-acetate (PMA, AppliChem, A0903), cells
were incubated for 2 h at 37°C in presence of 100 nM PMA.
The PMA stock solution (10 mM) was prepared immediately
before usage.
Protein preparation/cloning and expression of IL-6,
sgp130Fc, sIL-6R and Hyper-IL-6. The proteins IL-6,
50 sIL-
6R,
51 sgp130Fc,
52 and Hyper-IL-6
24 were produced as previously
described.
Fill in reaction and in vitro transcription. The initial single
stranded DNA library R1 contained 60 randomized nucleotides
(N60) flanked by two constant primer-binding sites. The forward
primer (T7 primer R1) contained the sequence for the T7 RNA
polymerase promoter region. The DNA library R1 was converted
into dsDNA by a two-step fill in reaction. First the ssDNA library
was hybridized with the reverse primer in a hybridization reaction:
equal amounts (1 mM) of DNA library R1 and reverse primer
(RT primer R1) were mixed in 1  PCR buffer B (Solis
BioDyne), heated to 80°C for 5 min and slowly cooled down
to RT. The second strand synthesis was completed using the
Klenow fragment (Thermo Fisher Scientific, EP0051) under the
following conditions: 1.25 U Klenow fragment per 100 mL;
0.5 mM hybridization product; 500 mM of each dNTP in
Klenow buffer (Thermo Fisher Scientific); temperature profile:
1 h 37°C, 10 min 75°C. Double stranded nucleic acids (0.1 mM)
were directly used for in vitro transcription by T7 RNA poly-
merase for 3 h at 37°C in transcription buffer (40 mM TRIS-
HCl, pH 7.9) containing T7 RNA polymerase (0.25 U/mL),
NTPs (2.5 mM each) and MgCl2 (15 mM). The derived RNA
library R1 was purified on 8% denaturing polyacrylamide gels.
Biotinylation of sIL-6R and immobilization on Streptavidin-
coated Dynabeads. For immobilization of a biotinylated target
protein on Streptavidin-coated magnetic beads (Dynabeads
1 M-
280 Streptavidin, Invitrogen, 112.06D) 100 mg of sIL-6R were
mixed with a 3-fold molar excess of Sulfo-NHS-LC-Biotin
(Thermo Fisher Scientific, 10538723) in a final volume of
100 mL selection buffer followed by incubation on ice for 15 min
and further 15 min at RT.
53 The excess of non-reacted and
hydrolyzed biotin reagent was removed by dialysis against selec-
tion buffer using a Slide-A-Lyzer
1 dialysis cassette (MWCO 10K;
Thermo Fisher Scientific). The biotinylated protein was immo-
bilized on 5 mg Dynabeads and suspended in selection buffer
(including 1.25 mg BSA/mL).
In vitro selection procedure. In the first round of the in vitro
selection process 500 pmol of the RNA library (~10
13 molecules)
were incubated with 100 pmol sIL-6R immobilized on magnetic
beads in selection buffer (containing 1 mg BSA/mL) for 30 min at
37°C. Unbound RNA molecules were removed by magnetic
separation. After washing with 200 mL selection buffer, bound
RNA molecules were eluted in 50 mL water by heating the sample
to 80°C for 3 min and amplified by reverse transcription and
polymerase chain reaction (RT-PCR). Therefore the following
RT-PCR reaction was prepared: 1  PCR buffer B; 0.2 First-
Strand Buffer (Invitrogen); forward and reverse primer (1 mM
each); 1.5 mM MgCl2; 0.3 mM dNTPs; 2 mM DTT. For reverse
primer hybridization the mixture was heated to 65°C for 5 min
and cooled down on ice. The RT-PCR was started after addition
of 15 U SuperScript
TM III Reverse Transcriptase (Invitrogen,
Table2. Oligonucleotides
Oligonucleotide Sequence (printed in 5’–3’ direction) Note
AIR-3A GGGGAGGCUGUGGUGAGGG (1)
G17U GGGGAGGCUGUGGUGAUGG (1)
G18U GGGGAGGCUGUGGUGAGUG (1)
G17U/G18U GGGGAGGCUGUGGUGAUUG (1)
DNA library R1 AATGCTAATACGACTCACTATAGG-
AAGAAAGAGGTCTGAGACATTCT–
N60–CTTCTGGAGTTGACGTTGCTT
(2)
T7 primer R1 AATGCTAATACGACTCACTATA-
GGAAGAAAGAGGTCTGAGACATT
(2)
RT primer R1 AAGCAACGTCAACTCCAGAAG (2)
(1) All RNAs were synthesized, optionally modified (5’-Biotin, 5’-Atto647N,
or 5’-Cy5), and purified by IBA. (2) DNA library R1, containing 60 rando-
mized nucleotides (N60), and corresponding primers were purchased
from Metabion. The T7 promoter region is underlined.
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18080–044) and 5 U FIREPol
1 (Solis BioDyne, 01–01–02000)
per 100 mL reaction. Following settings were used: 10 min at
54°C for the reverse transcription; for PCR amplification: 30 sec
at 95°C; 30 sec at 60°C and 30 sec at 72°C for an appropriate
number of PCR cycles. For the subsequent rounds of selection the
derived dsDNAs were transcribed into a RNA library as described
above. To increase the stringency during the following rounds of
selection the number of washing steps was raised by one each
round. After 16 rounds of this in vitro selection process the
dsDNA library was cloned via TOPO TA Cloning (pCR2.1,
Invitrogen, K456001) and individual clones were sequenced.
Filter retention assay (FRA). To investigate the binding of
RNA molecules to the target protein, filter retention assays were
performed. Nucleic acids were radioactively labeled during T7
transcription by incorporation of [a-
32P]-ATP (3,000 Ci/mmol,
Hartmann Analytic, SCP-207). After gel purification, constant
amounts of labeled RNA (,1 nM) were incubated with increas-
ing amounts of the target protein (0–500nM) in 1 selection
buffer. After incubation the samples were filtered through a pre-
equilibrated nitrocellulose membrane (0.45 mm, Carl Roth) on a
vacuum manifold (Minifold
1 I Dot-Blot-System; Schleicher &
Schuell) and washed four times with selection buffer. The
nitrocellulose membrane was dried and exposed to a phosphor-
imaging screen (Bio-Rad). The amount of radioactively labeled
RNA on the filter was quantified using Quantity One
1 software
(Version 4.6.6, Bio-Rad) and used for the calculation of the
bound RNA fraction. For the determination of characteristic Kd-
values (dissociation constants) and Bmax-values (maximal binding)
data were fitted using a one site-binding model with the aid of the
program GraphPad Prism. The following equation was used:
RNAbound =( B max  cProtein)/( K d +c Protein)
Electrophoretic mobility shift assay (EMSA). RNA-protein-
interactions were investigated using a native electrophoretic
mobility shift assay. Radioactively labeled RNAs (,1 nM) were
incubated with proteins of interest in selection buffer for 30 min
at room temperature. 6 DNA Loading Dye (Thermo Fisher
Scientific, R0611) was added and samples were loaded on 5%
non-denaturing polyacrylamide gels (acrylamide/bisacrylamide
37.5:1) and electrophoresed at 60 V for 2–3 h in 1 TBE
buffer. The gel was dried on a vacuum dryer at 70°C for 2 h,
exposed to a phosphor imager screen over night, and detected as
described above.
Circular dicroism (CD) spectroscopy. For CD spectroscopy
RNAs were dissolved in four different buffers (PBS, 50 mM
TRIS-HCl (pH 7.5), and 50 mM TRIS-HCl (pH 7.5) optionally
containing 100 mM KCl or NaCl; final RNA concentration
5 mM). CD spectra were recorded using a Jasco J-815 CD
spectrometer at 25°C. Each spectrum was accumulated for two
times and corresponding values were averaged.
UV spectroscopy. For UV-melting experiments RNAs were
dissolved in 10 mM TRIS-HCl (pH 7.5) optionally containing
1 mM, 5 mM or 10 mM KCl. RNA concentrations ranged from
1 mMt o1 0mM. UV-melting studies of prepared RNAs were con-
ducted on a Varian Cary Bio 300 UV-Visible Spectrophotometer
with a temperature controller. Each sample (1200 mL) was filled
into a quartz cuvette (1-cm path length), covered with a thin layer
of mineral oil, transferred to the spectrophotometer, heated to
80°C and cooled down to 20°C for two times with a heating or
cooling rate of 0.5°C min
21. Absorbance was recorded at 295 nm
every 30 sec. Each melting curve was analyzed using the method
of van’t Hoff to determine the Tm value.
54,55
Flow cytometry. The presentation of human IL-6R and human
gp130 on the surface of BAF/gp130/IL6R/TNF or BAF/gp130
cells was determined by flow cytometry using antibodies specific
for human IL-6R and human gp130, respectively. Five hundred-
thousand cells were washed two times in 1 selection buffer and
suspended in 350 mL1 selection buffer. After addition of
a murine primary antibody binding to human IL-6R (B-R6,
antibodies-online, ABIN123898) or human gp130 (R&D
Systems, MAB228), respectively, or an isotype-specific control
antibody (Tetra-His antibody, Qiagen, 34670), in final concen-
trations of 0.3 ng/mL, cells were incubated for 30 min on ice.
Three washing steps with 350 mL1 selection buffer followed.
Cells were incubated with an APC- or FITC-labeled secondary
antibody (1:350 diluted; Th.Geyer, 550826, or Santa Cruz
Biotechnology, sc-2078, respectively) in 350 mL1 selection
buffer for 30 min at 4°C. Cells were washed as previously
described and resuspended in 350 mL1 selection buffer.
Fluorescence intensities were determined by a FACSCalibur
flow cytometer (BD Biosciences) counting 10.000 events and
evaluated using the BD CellQuest software (Version 3.2.1).
Binding of the IL-6R-specific aptamer AIR-3A or its variant
G17U to the surface of defined cells was determined by flow
cytometry. Therefore 500,000 cells were washed twice in 1 
selection buffer, serum containing or lacking culture medium.
Cy5- or Atto
1647N-labeled RNAs (25 nM each) were incubated
with 500,000 cells in corresponding solutions between 1 min and
8 h at 37°C or 4°C. Afterwards cells were washed, suspended in
350 mL of the same buffer and analyzed by flow cytometry as
described above.
To measure the relative affinities of Atto
1647N-labeled
aptamer AIR-3A and the variant G17U for BAF/gp130/IL6R/
TNF-cells, increasing concentrations (0 nM–150 nM) of
corresponding RNAs were mixed with 500,000 cells each. After
incubation at 37°C for 20 min cells were treated as previously
described and analyzed by flow cytometry. Median fluorescence
intensities (MFI) were plotted against RNA concentrations using
GraphPad Prism software.
Internalization studies of aptamer AIR-3A using laser
scanning microscopy. To visualize the internalization of aptamer
AIR-3A of into BAF/gp130/IL6R/TNF-cells 500,000 cells were
incubated with Atto
1647N-labeled aptamer AIR-3A (25 nM) in
350 mL1 selection buffer for 30 min at 37°C. Cells were
washed two times with 350 mL1 selection buffer and
resuspended in 50 mL1 selection buffer only.
Suspensions were directly placed on a glass slide and covered by a
coverslip. Samples were imaged with LSM 510 ConfoCor2 system
(CarlZeiss).Basicadjustmentsused:HeNe-Laser(633nm),5–15%
laser power, 92–896 mm pinhole diameter, beam splitters: HFT
514/633 nm and NFT 545 nm, LP 650 nm filter.
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Binding and internalization studies of aptamer-streptavidin-
complexes. For preparation of aptamer-streptavidin-complexes,
biotinylated RNAs (30 mM) and biotinylated fluorescent dye
Atto635 (10 mM; ATTO-TEC, AD 635–71) were mixed in 1 
selection buffer. Streptavidin (New England Biolabs, N7021S)
was added to a final tetrameric concentration of 10 mM and the
reaction mixture was incubated for 10 min at room temperature.
The formation of fluorescently labeled aptamer-streptavidin-
complexes was analyzed by native PAGE (10% PAA; acryla-
mide/bisacrylamide 37.5:1). Resulting bands were visualized by
fluorescence detection (filter color: red; BP: 695 nm) using a
VersaDoc Imaging System (Bio-Rad).
Binding of Alexa635-labeled complexes to BAF/gp130/IL6R/
TNF-cells was tested by flow cytometry. Complexes (25 nM)
were mixed with 500,000 cells in selection buffer, incubated for
20 min at 37°C. Cells were analyzed as described above.
To visualize the internalization of aptamer-streptavidin-
complexes into BAF/gp130/IL6R/TNF-cells 500,000 cells were
incubated with the Atto635-fluorescently labeled complexes
(25 nM) in 350 mL1 selection buffer for 10 min at 4°C or
37°C. In order to distinguish between cell surface bound
complexes and intracellular complexes, cells were optionally
treated with trypsin (PAA, L11–004). This protease unspecifically
degrades proteins of the cell surface and protein components
of the complexes outside the cells. Cells were washed two times
with 350 mL1 selection buffer and resuspended in 50 mL1
selection buffer only.
Suspensions were placed on glass slides, covered by coverslips
and imaged using the LSM 510 ConfoCor2 system (Carl Zeiss) as
described above.
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